These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17515569)

  • 1. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
    Kyle RA; Yee GC; Somerfield MR; Flynn PJ; Halabi S; Jagannath S; Orlowski RZ; Roodman DG; Twilde P; Anderson K;
    J Clin Oncol; 2007 Jun; 25(17):2464-72. PubMed ID: 17515569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Anderson K; Ismaila N; Flynn PJ; Halabi S; Jagannath S; Ogaily MS; Omel J; Raje N; Roodman GD; Yee GC; Kyle RA
    J Clin Oncol; 2018 Mar; 36(8):812-818. PubMed ID: 29341831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
    J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
    Terpos E; Sezer O; Croucher PI; García-Sanz R; Boccadoro M; San Miguel J; Ashcroft J; Bladé J; Cavo M; Delforge M; Dimopoulos MA; Facon T; Macro M; Waage A; Sonneveld P;
    Ann Oncol; 2009 Aug; 20(8):1303-17. PubMed ID: 19465418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
    Hillner BE; Ingle JN; Chlebowski RT; Gralow J; Yee GC; Janjan NA; Cauley JA; Blumenstein BA; Albain KS; Lipton A; Brown S;
    J Clin Oncol; 2003 Nov; 21(21):4042-57. PubMed ID: 12963702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma.
    Krstevska S; Stavric SG; Cevrevska L; Georgjievski B; Karanfilski O; Sotirova T; Balkanov T
    Med Arch; 2015 Dec; 69(6):367-70. PubMed ID: 26843726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
    Hoff AO; Toth BB; Altundag K; Johnson MM; Warneke CL; Hu M; Nooka A; Sayegh G; Guarneri V; Desrouleaux K; Cui J; Adamus A; Gagel RF; Hortobagyi GN
    J Bone Miner Res; 2008 Jun; 23(6):826-36. PubMed ID: 18558816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
    Pavkovic M; Petrushevska G; Jovanovic R; Karanfilski O; Cevreska L; Stankovic S; Stojanovic A
    Prilozi; 2010; 31(2):39-49. PubMed ID: 21258276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Gollbach KL; Hayman SR; Kumar S; Lust JA; Rajkumar SV; Russell SJ; Witzig TE; Zeldenrust SR; Dingli D; Bergsagel PL; Fonseca R; Reeder CB; Stewart AK; Roy V; Dalton RJ; Carr AB; Kademani D; Keller EE; Viozzi CF; Kyle RA
    Mayo Clin Proc; 2006 Aug; 81(8):1047-53. PubMed ID: 16901028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.